FDA clears United Therapeutics’ inhaled PAH combination therapy for Phase 1 trial
United Therapeutics received U.S. Food and Drug Administration clearance to begin a Phase 1, open‑label, single‑ascending‑dose study of Treprostinil‑Iloprost SMI, an investigational inhaled combination of two prostacyclin analogues for pulmonary arterial hypertension. The trial will assess safety, tolerability and pharmacokinetics in healthy volunteers, with a planned Phase 2 study in PAH patients in 2027 if results are positive. Company executives highlighted the therapy as a potential first‑in‑class as‑needed treatment for symptom flare‑ups.
Why it matters
The clearance enables United Therapeutics to advance a novel PAH therapy that could expand its rare‑disease pipeline and generate future revenue if successful, though no immediate financial impact is disclosed. Analysts have not provided a valuation change, so the event’s effect is limited to pipeline development expectations.
Key facts
- 1The FDA granted clearance for United Therapeutics to start a Phase 1 trial of Treprostinil‑Iloprost SMI. stocktitan.net
- 2The Phase 1 study is open‑label, single‑ascending‑dose and will evaluate safety, tolerability and pharmacokinetics in healthy volunteers. investing.com
- 3United Therapeutics plans to commence a Phase 2 study in PAH patients in 2027, contingent on successful Phase 1 results. stocktitan.net
- 4Treprostinil‑Iloprost SMI combines the prostacyclin analogues treprostinil and iloprost and is delivered via a soft‑mist inhaler for as‑needed use. rttnews.com
- 5PAH affects approximately 500,000 individuals worldwide. investing.com
- 6UTHR stock closed at $591.20, down 0.28% on the day of the announcement. rttnews.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.